Qlife carries out a rights issue of units of approximately SEK 76 million and brings forward the publication of the interim report for the first half of 2022
The board of directors of Qlife Holding AB (“Qlife” or the “Company”) has today, 24 August 2022, subject to approval by the extraordinary general meeting on 27 September 2022, resolved to carry out an issue of units, consisting of shares and warrants, with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Rights Issue mainly intends to finance the approval of a CRP test for self-test use in the European markets as well as completion and filing of clinical studies for CE approval of a PHE test for self-test use. Members of the Company’s board of directors